Open Access
J Oral Med Oral Surg
Volume 27, Number 3, 2021
Article Number 38
Number of page(s) 5
Published online 14 July 2021
  1. Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 2018;10:209–23. [CrossRef] [PubMed] [Google Scholar]
  2. VIDAL − XGEVA 120 mg sol inj − Indications [Internet]. (consulted 28 Aug 2020) [Google Scholar]
  3. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (Murine/Human) RANKL*. J Bone Miner Res 2009;24:182–95. [CrossRef] [PubMed] [Google Scholar]
  4. HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique; Commission de la transparence, XGEVA, Avis 11 Avril 2012. [Internet].∼/media/amgen/full/www-amgen-com/www-amgen-fr/downloads/fr-pdf-022.ashx?la=fr-FR (consulted 28 Aug 2020) [Google Scholar]
  5. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet Lond Engl 2011;377:813–22. [Google Scholar]
  6. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125–32. [CrossRef] [PubMed] [Google Scholar]
  7. Aljohani S, Gaudin R, Weiser J, Tröltzsch M, Ehrenfeld M, Kaeppler G, et al. Osteonecrosis of the jaw in patients treated with denosumab: a multicenter case series. J Cranio-Maxillofac Surg 2018;46:1515–25. [Google Scholar]
  8. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 2014;72:1938–56. [CrossRef] [PubMed] [Google Scholar]
  9. Limones A, Sáez-Alcaide Lm, Díaz-Parreño Sa, Helm A, Bornstein Mm, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: a systematic review and meta-analysis. Med Oral Patol Oral Cirugia Bucal 2020;e326–36. [Google Scholar]
  10. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, Reid IR, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30:3–23. [CrossRef] [PubMed] [Google Scholar]
  11. Xgeva® 120 mg, solution injectable (denosumab) − Ajout d'une nouvelle contre-indication et remise d'une carte d'information patient − Lettre aux professionnels de santé − ANSM: Agence nationale de sécurité du médicament et des produits de santé [Internet]. (consulted 28 Aug 2020). [Google Scholar]
  12. Société Française de Stomatologie, Chirurgie Maxillo-Faciale et Chirurgie Orale. Ostéonécrose des mâchoires en chirurgie oromaxillofaciale et traitements médicamenteux à risque (antirésorbeurs osseux, antiangiogéniques), Recommandations de Bonne Pratique. July 2013. 49 p (consulted 28 Aug 2020). [Google Scholar]
  13. Chen Q, Hu C, Liu Y, Song R, Zhu W, Zhao H, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: a randomized, single-blind, placebo-controlled study. PLoS ONE 2018;22;13:1–13. [Google Scholar]
  14. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997;1;12:1700–7. [CrossRef] [PubMed] [Google Scholar]
  15. Narayanan P. Denosumab: a comprehensive review. South Asian J Cancer 2013;2:272–7. [CrossRef] [PubMed] [Google Scholar]
  16. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008;49:2156–62. [CrossRef] [PubMed] [Google Scholar]
  17. Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 2010;68:107–10. [CrossRef] [PubMed] [Google Scholar]
  18. Schubert M, Klatte I, Linek W, Müller B, Döring K, Eckelt U, et al. The saxon bisphosphonate register − therapy and prevention of bisphosphonate-related osteonecrosis of the jaws. Oral Oncol 2012;48:349–54. [CrossRef] [PubMed] [Google Scholar]
  19. Heufelder M, Hendricks J, Remmerbach T. Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw. Oral Maxillofac Surg 2014;117:e429-35. [Google Scholar]
  20. Mozzati M, Arata V, Gallesio G. Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporos Int 2013:1707–12. [CrossRef] [PubMed] [Google Scholar]
  21. Vieira AE, Repeke CE, Ferreira Junior S de B, Colavite PM, Biguetti CC, Oliveira RC, et al. Intramembranous bone healing process subsequent to tooth extraction in mice: micro-computed tomography, histomorphometric and molecular characterization. PLoS ONE 2015;10:1-22. [CrossRef] [PubMed] [Google Scholar]
  22. Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009;20:1303–17. [CrossRef] [PubMed] [Google Scholar]
  23. Khan AA. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom 2017;20:8–24. [CrossRef] [PubMed] [Google Scholar]
  24. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. J Am Dent Assoc 2011;142:1243–51. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.